person · Reporting owner
Johnson Michael Perkins
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,575.687 |
Reported balance
After 2026-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-14 · Exercise / conversion · Acquired 176 · Balance 2,575.687 F1: Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares. |
| Common StockSEC Table I · non-derivative | Direct | 2,754.687 |
Reported balance
After 2026-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 179 · Balance 2,754.687 |
| Common StockSEC Table I · non-derivative | Direct | 2,972.687 |
Reported balance
After 2026-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-14 · Exercise / conversion · Acquired 218 · Balance 2,972.687 |
| Common StockSEC Table I · non-derivative | Direct | 2,794.687 |
Reported balance
After 2026-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-02-14 · Tax withholding · Disposed 178 · Balance 2,794.687 F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 3,207 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Grant · Acquired 3,207 · Balance 3,207 F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 770 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Grant · Acquired 770 · Balance 770 F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 176 |
Reported balance
After 2026-02-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-14 · Exercise / conversion · Disposed 176 · Balance 176 F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 356 |
Reported balance
After 2026-02-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-14 · Exercise / conversion · Disposed 179 · Balance 356 F7: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 652 |
Reported balance
After 2026-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-14 · Exercise / conversion · Disposed 218 · Balance 652 F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares.
F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027.
F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
F7: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 10 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652 Underlying: Common Stock · 218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 9 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356 Underlying: Common Stock · 179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 8 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 178 | $629.35 | $112,024.30 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · nonDerivative · entry 4 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,794.687 F2 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · nonDerivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,972.687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · nonDerivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,754.687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · nonDerivative · entry 1 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575.687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 770 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 7 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770 Underlying: Common Stock · 770 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 6 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,207 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000022 · wk-form4_1771374639.xml · derivative · entry 5 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,207 Underlying: Common Stock · 3,207 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 3,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-25-000102 · wk-form4_1748984404.xml · derivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,382 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2025. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2025. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2025. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,499 | $513.36 | $769,526.64 |
DisclosureSEC source: 0000874716-25-000102 · wk-form4_1748984404.xml · nonDerivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,365.3419 F2 · price: Closing price of Issuer common stock on the Nasdaq market on May 30, 2025. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 3,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000102 · wk-form4_1748984404.xml · nonDerivative · entry 1 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,864.3419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · derivative · entry 8 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 535 Underlying: Common Stock · 179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · derivative · entry 7 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 118 | $444.53 | $52,454.54 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · nonDerivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467.3419 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · nonDerivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585.3419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · nonDerivative · entry 1 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406.3419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 47 shares purchased under the Issuer Employee Stock Purchase Plan on March 29, 2024, June 28, 2024, September 31, 2024 and December 31, 2024. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · derivative · entry 6 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 870 Underlying: Common Stock · 870 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · derivative · entry 5 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,657 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000025 · wk-form4_1739932992.xml · derivative · entry 4 Johnson Michael Perkins · CIK 0001917747 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,657 Underlying: Common Stock · 3,657 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · derivative · entry 6 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528 Underlying: Common Stock · 176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 714 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · derivative · entry 5 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714 Underlying: Common Stock · 714 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · derivative · entry 4 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,132 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · derivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,132 Underlying: Common Stock · 3,132 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 60 | $560.56 | $33,633.60 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · nonDerivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183.3419 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000037 · wk-form4_1708124148.xml · nonDerivative · entry 1 Johnson Michael Perkins · CIK 0001917747 · EVP and CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243.3419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 51.542 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2023, June 30, 2023, September 29, 2023 and December 29, 2023. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 4 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,086 Underlying: Common Stock · 704 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 804 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 3 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804 Underlying: Common Stock · 804 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,346 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002391 · doc1.xml · derivative · entry 2 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,346 Underlying: Common Stock · 4,346 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 3,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-012326 · doc1.xml · derivative · entry 1 Johnson Michael Perkins · CIK 0001917747 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025. F2 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.